Clinical Lymphoma, Myeloma & Leukemia
Publisher: Elsevier · ISSN 2152-2650 · 71 articles
- SOHO State of the Art Updates and Next Questions| Mediastinal Gray-zone Lymphoma: Novel Biologic Insights and Updates on How Best to Approach This Rare Entity
- SOHO State of the Art Updates and Next Questions | Individualizing Treatment Selection in Myelofibrosis
- Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success
- Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study
- In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma
- KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome
- Safe Integration of Radiation Therapy With Bispecific Antibodies in Relapsed/Refractory B-cell Lymphomas
- V-RULES: Real-World Effectiveness and Safety of CPX-351 for First-Line Treatment of Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes in the US
- Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes
- SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis
- The Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia
- Early Deaths in Acute Promyelocytic Leukemia in the Era of All-Trans Retinoic Acid: National Real-World Study in Algeria
- Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study
- Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
- Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US
- Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network
- Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada
- SOHO State of the Art Updates and Next Questions | Best of Cell Therapy for Lymphoma
- A Real-World Experience With First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma
- Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO
- Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas
- Real-World Experience of Using Next-Generation-Sequencing in Multiple Myeloma Diagnostics in the UK National Health Service
- Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial
- FcRH5-Targeted Therapy in Multiple Myeloma: Evolving Clinical Strategies and Resistance From IMS 2026
- How Many Lines of Therapy Do Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receive in Routine Clinical Practice in the United States? Real World Evidence From the Targeted Therapy Era
- Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients
- Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial
- GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026
- A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations